Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

Haematologica. 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. Epub 2010 Apr 23.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Amino Acid Substitution
  • Female
  • Gene Frequency
  • Humans
  • Hydroxyurea / therapeutic use*
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Polycythemia Vera / drug therapy
  • Polycythemia Vera / enzymology
  • Polycythemia Vera / genetics*
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / enzymology
  • Thrombocythemia, Essential / genetics*
  • Treatment Outcome
  • Young Adult

Substances

  • Nucleic Acid Synthesis Inhibitors
  • Janus Kinase 2
  • Hydroxyurea